Pulmonary drug delivery is an alternative to oral drug delivery. Pulmonary drug delivery is primarily advantageous for the treatment of respiratory diseases due to systemic administration via fast absorption by the alveolar region. The pulmonary drug delivery method depsends on the development of simple, cost effective and easy to use devices. These devices are designed to facilitate consistent drug delivery with increased lung penetration and multi-dosage facilities. Currently, manufacturers are concentrating on the development of small, portable devices that encourage higher patient compliance. The World Health Organization (WHO) estimates that there were approximately 251 million people suffering from COPD globally in 2016. It is estimated by the WHO that nearly 3.17 million deaths occurred in 2015 due to the disease itself. The primary cause of the disease is smoking tobacco. The growing number of smokers in developing economies is increasing the incidence of the disease.
The market for pulmonary drug delivery systems is witnessing growth due to the rising prevalence of respiratory disorders such as asthma, COPD and other chronic illnesses. Other factors that are driving the growth of the market are the emergence of novel inhaler designs and increased use of non-invasive drug delivery methods.
The pulmonary drug delivery systems market is estimated at REDACTED in 2017, growing at acompound annual growth rate (CAGR) of REDACTED to reach REDACTED in 2022.Report Scope:
This report will provide a detailed look at the pulmonary drug delivery systems market, highlighting major pulmonary diseases with detailed epidemiology for major disease areas such as asthma, COPD and cystic fibrosis. The report includes an industry-wide assessment of the novel products, launches, recent approvals, research and development pipeline, and blockbuster drugs.
In the report the regulatory scenario of pulmonary drug delivery systems is discussed for device type. This will include products approved by regulatory authorities in recent years. Products under development or in different stages of clinical trials are analyzed in the Pipeline Analysis section.
A discussion of the major players is included in the Competitive Landscape section. The Competitive Landscape section provides trends in product launch, collaborations, mergers and acquisitions, and other agreements. Company profiles of major players operating in the pulmonary drug delivery systems market are included with an overview, key product offerings, financials, strategies, strength, weakness, opportunities and threats (SWOT) and developments. The report will be useful for analysis of the leading products and will enable readers to recognize growing brands, key device types and leading manufacturing companies with significant market share.
– 74 tables
– A detailed overview and analysis of the global markets for pulmonary drug delivery systems
– Analyses of global market trends, with data from 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2022
– Assessments of pulmonary drug delivery systems by regions, delivery systems/types, and disease areas
– A look at the regulatory environment, which has been a driving force in the healthcare industry
– Reviews of key developments, novel product innovations, and recent strategic industry activities of major players across various product categories
– Detailed profiles of major vendors in the market, including 3M Pharmaceuticals Inc., AstraZeneca plc, Cipla Inc., GlaxoSmithKline plc and Lupin Ltd3M PHARMACEUTICALS, INC.
BOEHRINGER INGELHEIM GMBH
DR. REDDY’S LABORATORIES LTD.
KONINKLIJKE PHILIPS N.V. (RESPIRONICS, INC.)
TEVA PHARMACEUTICAL INDUSTRIES, LTD.
VECTURA GROUP PLC
Table of Content: Key Points
Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Chapter 2 Summary and Highlights
Chapter 3 Market Dynamics and Technology Background
Market Definition and Overview
Mechanism of Action
Pulmonary Conditions and Therapies
Introduction to the Respiratory System
Market Driving Factors and Trends
Improved Patient Compliance and Ease of Use Leading to Adoption of Inhalation Products
Cost Pressure on Countries Imposing Adoption of Cost-Effective Devices
Rising Incidence of Asthma and COPD in Developing and Developed Regions
Competition from Generics on the Rise Due to Patent Expiry of Blockbuster Products
Introduction of Smart Nebulizers
Regulation and Legislation
Chapter 4 Market Breakdown by Pulmonary Drug Delivery Systems
Overview of Inhalation Techniques
Leading Respiratory Products
Get in touch:
Company Name: Wiseguyreports.com
Contact Person: Norah Trent
Email: Send Email
Phone: +1 646 845 9349, +44 208 133 9349